Results 71 to 80 of about 113,281 (294)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS

Jurnal Ilmiah Medicamento, 2018
Diabetes mellitus (DM) merupakan penyakit gangguan metabolisme glukosa yang dicirikan dengan gangguan sekresi dan resistensi insulin. Jalur pengobatan DM baru pada sistem increatin dengan penghambatan terhadap DPP-4 telah dikembangkan dan terbukti ...
Martina Kurnia Rohmah
doaj   +5 more sources

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

, 2010
James E Foley1, Jens Jordan21Clinical Research and Development, Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA; 2Institute for Clinical Pharmacology, Hannover Medical School, Hannover, GermanyAbstract: Various factors may confound how
James E Foley, Jens Jordan
core  

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

, 2011
International audienceInhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode of action related to the stabilization of the active forms of DPP-4-sensitive hormones such as the incretins that enhance glucose ...
Pierre Cattan, Thierry Sulpice, Myriam Masseboeuf, Jens J. Holst, Waget, Aurélie, Holst, Jens Juul, Drucker, Daniel J, Magnan, Christophe, Rémy Burcelin, Sulpice, Thierry, Mélis Karaca, Adriano Maida, Castel, Julien, Maida, Adriano, Burcelin, Rémy, Mattieu Armanet, Cattan, Pierre, Julien Castel, Holst, Jens J, Celine Garret, Masseboeuf, Myriam, Armanet, Mattieu, Payros, Gaëlle, Cabou, Cendrine, Christophe Magnan, Cendrine Cabou, Aurélie Waget, Gaëlle Payros, Daniel J. Drucker, Garret, Celine, Karaca, Mélis   +30 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Concomitant Use of DPP‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study

Clinical and Translational Science
Oxaliplatin‐induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem.
Yusuke Koura, Keisuke Mine, Shunsuke Fujita, Takehiro Kawashiri, Yusuke Mori, Mami Ueda, Risa Kaneko, Takeshi Hirota, Mayako Uchida, Daisuke Kobayashi   +9 more
doaj   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study

ERJ Open Research
Aims COPD is a comorbid condition often associated with type 2 diabetes (T2D) and cardiovascular diseases, but few studies have observed the impact of various antidiabetic drugs in patients with COPD and T2D.
Fu-Shun Yen, James Cheng-Chung Wei, Fu-Shun Ko, Yuhan Huang, Hei-Tung Yip, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +7 more
doaj   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

BMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong, Zhifeng Shi, Mengqing Li, Jien Han, Haoyan Chen, Maofei Ran, Shaojian Zhong, Limin Ma, Chengyun Ning, Youzhun Fan, Zhenghua Tang, Peng Yu   +11 more
wiley   +1 more source

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

Cardiovascular Diabetology, 2017
Background Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes.
Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar, Wei-Chun Huang   +9 more
doaj   +1 more source